CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company with a focus on respiratory and CNS disorders, today announced an update on the development of its most advanced prescription product candidate for the treatment of allergic rhinitis. Collegium previously announced that it had acquired, from Muro Pharmaceutical, Inc., all rights to its Tri-Nasal® (triamcinolone acetonide, USP) Nasal Spray, including the product’s approved NDA and the right to market the product. Triamcinolone acetonide is the same active ingredient found in Nasacort® AQ (Aventis) which had 2006 US sales of approximately $350 million according to IMS Health. Tri-Nasal® received FDA approval as a once-daily, intranasal steroid medication for the treatment of seasonal and perennial allergic rhinitis in adults and children over age 12. Tri-Nasal® was then the subject of a Class III voluntary recall for low potency found in certain lots of the product.
